Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [04/30/2025 14:55 PDT] Immix Biopharma, Inc. (NASDAQ:IMMX), Up By 100% ($1.71) From $1.71 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/23/2025 07:31 PDT] IMMX Expected to Trade Up After Bullish Patterns Develop
• [03/19/2025 10:29 PDT] Immix Biopharma, Inc. (NASDAQ:IMMX), Up By 100% ($1.65) From $1.65 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [03/07/2025 07:08 PST] IMMX Expected to Trade Up After Bullish Patterns Develop
• [03/03/2025 07:42 PST] IMMX Expected to Trade Up After Bullish Patterns Develop